ESR1 and breast carcinoma: In addition, knockdown of ERα expression with ERα‐shRNA significantly decreased the number of viable ZR‐75‐1/R and MCF‐7/R cells (Figure 5F and G), indicating that IBC could down‐regulate CD44 expression by the ERα pathway to sensitize of resistant breast cancer cells to paclitaxel.